Friday, 21 May 2010 18:39


Written by Law Offices Of Gary Green

Fosamax has been widely used to prevent or treat osteoporosis. It is also used for the treatment of Paget’s Disease. Fosamax has been associated with the development of bone loss in the jaw, also called osteonecrosis of the jaw (ONJ) or “jawbone death.” Criteria for Fosamax cause of action include:

  • Diagnosed with osteoporosis or Paget’s Disease
  • No kidney disease.
  • Development of osteonecrosis of the jaw (ONJ)
  • Long-term use of Fosamax
  • Atrial Fibrillation
  • Esophageal Tumors and/or cancer
  • Unusual Bone Fractures
  • Severe Bone, Joint and Muscle Pain

If you or someone you know suffered bone loss in the jaw after taking Fosamax, contact Law Offices of Gary Green toll free at 1-888-4GARYGREEN or send us an e-mail at to discuss your legal options without obligation.

Friday, 21 May 2010 18:36


Written by Law Offices Of Gary Green

As if patients facing heart bypass surgery did not already have enough to worry about, there is now a chance that Trasylol, a drug used to prevent blood loss, might actually increase their risk of kidney problems, heart attacks, and strokes. Patients who suffered serious injuries as a result of Trasylol are now filing lawsuits against the drug’s maker, alleging it knew about the risks but failed to warn patients.

The first lawsuits against Bayer, maker of Trasylol, were filed earlier this year.

A study published in the New England Journal of Medicine, (January 26, 2007) found that Trasylol had an increased risk of kidney failure, stroke, and degenerative brain disease. The study concluded, “The association between Aprotinin (Trasylol) and serious end-organ damage indicates that continued use is not prudent. In contrast, the less expensive generic medications aminocaproic acid and tranexamic acid are safe alternatives.”

The study found the increased risks of serious injury were significant. Trasylol was found to have a 55 percent increased risk of heart failure and a 181 percent increased risk of stroke or encephalopathy (degenerative brain disease). The research team estimated that up to 10,000 patients now require dialysis because of Trasylol.

Furthermore, a study published in the Journal of the American Medical Association found Trasylol was associated with a 48 percent increased risk of dying within five years of coronary artery bypass surgery. In fact researchers noted, as reported in The New York Times, that replacing Trasylol with other drugs for a year would prevent 10,000 deaths worldwide over the next five years.

Questions have been raised about what Bayer knew about the risks of Trasylol and when officials knew it. Allegations of withholding information from the U.S. Food and Drug Administration (FDA) have been made, although it is not clear whether the omission was intentional or erroneous. Despite a safety meeting with FDA officials, Bayer representatives failed to mention that their company had undertaken a safety study of Trasylol. Preliminary findings of that study found an increased risk of death, kidney damage, stroke, and congestive heart failure. Yet Bayer did not inform the FDA of this data at the safety meeting.

If you have suffered kidney failure, heart problems, or other permanent complications after surgery, please contact us at

Friday, 21 May 2010 18:32


Written by Law Offices Of Gary Green

Avandia is widely used to treat patients with Type II Diabetes Mellitus. Avandia has been associated with a significant increase in the risk of myocardial infarctions and an increase in the risk of death from cardiovascular causes. Criteria for an Avandia cause of action include:

  • Diagnosed with Type II Diabetes
  • Avandia use for at least twelve weeks
  • 50 years old or younger
  • Non-smoker
  • Death from cardiac event
  • Myocardial infarction (MI)/heart attack resulting in death or disability
  • Congestive heart failure (CHF) resulting in death or disability
  • Cardiomyopathy

If you or someone you know took Avandia and think you may have a claim, contact Law Offices of Gary Green toll free at 1-888-4GARYGREEN or send us an e-mail at